-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
An investigative article published in the British Medical Journal (BMJ) on November 2, 2021 [1] received much attention.
The information in the article comes from a disclosure by a regional director of the research organization Ventavia Research Group
Poor laboratory management
Poor laboratory managementVentavia states on its website that it is the largest private clinical research company in Texas
Fear of FDA inspections
Fear of FDA inspectionsDuring the meeting in late September, Jackson and Ventavia executives discussed the possibility of FDA inspections several times
Complaint letter to FDA
Complaint letter to FDAJackson wrote in an email to the FDA on September 25 that Ventavia has recruited more than 1,000 participants in three venues
Participant was left in the corridor after receiving the injection, without clinical staff monitoring
Lack of timely follow-up of patients with adverse events
Scheme deviation not reported
The vaccine is not stored at the proper temperature
The laboratory samples are mislabeled, and
These types of issues have been reported to Ventavia employees
A few hours later, Jackson received an e-mail from the FDA, thanking her for her concern, and notifying her that the FDA was unable to comment on the possible investigation
Evidence from other employees
Evidence from other employeesIn recent months, Jackson has reconnected with several former Ventavia employees
[1] Thacker P D.
[1] Thacker P D.
Covid-19: Researcher blows the whistle on data integrity issues in Pfizer's vaccine trial BMJ 2021; 375 :n2635 doi:10.
1136/bmj.
n2635